Business Description
Northwest Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US66737P6007
Total Employee Number:
105Description
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -0.63 | |||||
Debt-to-Equity | -1.27 | |||||
Debt-to-EBITDA | -1.98 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -27.65 | |||||
Beneish M-Score | -0.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 29.2 | |||||
3-Year EPS without NRI Growth Rate | 10.8 | |||||
3-Year FCF Growth Rate | 16.5 | |||||
3-Year Book Growth Rate | 31.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.45 | |||||
9-Day RSI | 45.87 | |||||
14-Day RSI | 45.19 | |||||
3-1 Month Momentum % | 21.95 | |||||
6-1 Month Momentum % | -20 | |||||
12-1 Month Momentum % | -3.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.07 | |||||
Quick Ratio | 0.07 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 | |||||
Shareholder Yield % | -8.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3574.02 | |||||
Net Margin % | -2931.73 | |||||
EBITDA Margin % | -2157.65 | |||||
FCF Margin % | -3298.37 | |||||
OCF Margin % | -3195.56 | |||||
ROA % | -88.13 | |||||
ROIC % | -61.43 | |||||
3-Year ROIIC % | -253.47 | |||||
ROC (Joel Greenblatt) % | -166.29 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 168.72 | |||||
EV-to-EBIT | -10.09 | |||||
EV-to-EBITDA | -10.93 | |||||
EV-to-Revenue | 235.86 | |||||
EV-to-FCF | -6.87 | |||||
Price-to-GF-Value | 0.63 | |||||
Earnings Yield (Greenblatt) % | -9.91 | |||||
FCF Yield % | -16.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Northwest Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.285 | ||
| EPS (TTM) (€) | -0.026 | ||
| Beta | -0.0192 | ||
| 3-Year Sharpe Ratio | -0.45 | ||
| 3-Year Sortino Ratio | -0.6 | ||
| Volatility % | 60.88 | ||
| 14-Day RSI | 45.19 | ||
| 14-Day ATR (€) | 0.028691 | ||
| 20-Day SMA (€) | 0.15935 | ||
| 12-1 Month Momentum % | -3.85 | ||
| 52-Week Range (€) | 0.1 - 0.38 | ||
| Shares Outstanding (Mil) | 1,643.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Northwest Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Northwest Biotherapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-29 14:00 | In 162 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.20 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 0.16 (+1.25%) | ||
| General meeting for 2025 | 2025-12-29 14:00 | 0.23 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.20 (+1.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.21 (+13.23%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.24 (-4.00%) | ||
| Annual report for 2024 | 2025-03-31 | 0.25 (+17.14%) |
Show
Entries
Northwest Biotherapeutics Inc Frequently Asked Questions
What is Northwest Biotherapeutics Inc(STU:NBYB)'s stock price today?
The current price of STU:NBYB is €0.15. The 52 week high of STU:NBYB is €0.38 and 52 week low is €0.10.
When is next earnings date of Northwest Biotherapeutics Inc(STU:NBYB)?
The next earnings date of Northwest Biotherapeutics Inc(STU:NBYB) is 2026-08-14 Est..
Does Northwest Biotherapeutics Inc(STU:NBYB) pay dividends? If so, how much?
Northwest Biotherapeutics Inc(STU:NBYB) does not pay dividend.
Press Release
Articles on Northwest Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers